Baseline Skin Examination Before JAK Inhibitor Therapy
Before initiating JAK inhibitor therapy, perform a baseline skin check for non-melanoma skin cancer (NMSC) in patients at risk, unless recently performed 1.
What to Examine
The baseline skin examination should be a full-body skin examination focusing on:
- Non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) - the primary concern in JAK inhibitor candidates
- All sun-exposed areas including scalp, face, neck, ears, dorsal hands, and forearms
- Areas of prior sun damage or actinic changes
- Any suspicious lesions requiring biopsy before treatment initiation
Who Needs This Examination
This screening is specifically recommended for patients at risk for NMSC, which includes:
- Fair-skinned individuals
- Those with significant sun exposure history
- Patients over 65 years (who already have age-related restrictions for some JAK inhibitors)
- History of prior skin cancers
- Immunosuppressed patients
- Those with multiple actinic keratoses (≥10 lesions indicates higher risk)
Clinical Rationale
JAK inhibitors carry theoretical increased risk of malignancy based on their mechanism of action and class-wide FDA warnings derived from rheumatoid arthritis trials 2. While recent real-world data in skin immune-mediated inflammatory diseases shows no increased malignancy risk over 2 years compared to conventional immunomodulators 3, baseline documentation remains essential for:
- Risk stratification - Identifying pre-existing lesions that could complicate monitoring
- Medicolegal protection - Documenting baseline status before immunomodulation
- Surveillance planning - Establishing a reference point for ongoing monitoring
Practical Implementation
- Timing: Perform unless "recently performed" - interpret this as within 6-12 months for average-risk patients, more recently for high-risk patients
- Documentation: Use body maps, photography, or detailed written descriptions of any concerning lesions
- Threshold for biopsy: Any suspicious lesion should be biopsied before JAK inhibitor initiation
- Concurrent screening: This examination should be performed alongside other baseline assessments (chest X-ray, hepatitis screening, tuberculosis testing, complete blood count, liver enzymes, lipid panel) 1, 2
Common Pitfalls
Do not skip this examination even in younger patients or those without obvious risk factors - dermatologist-performed total body skin examinations identify 51% of skin cancers that patients and referring providers miss 4. Complete skin examination in dermatology patients reveals unsuspected malignancies in 0.6-3.3% of cases 5, and melanomas found by clinicians have significantly thinner Breslow depth (0.53 mm vs 1.04 mm) than those identified by patients 4.
The examination need not be performed by a dermatologist for average-risk patients - primary care physicians can perform adequate screening, though sensitivity ranges from 42-100% for melanoma detection 6. Refer to dermatology if multiple suspicious lesions are present, patient has history of melanoma or multiple NMSCs, or if clinical expertise is limited.